Petros Pharmaceuticals, Inc.
PTPI
$0.01
$0.001.41%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | 725.40K | 2.30M | 3.72M | 5.11M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 725.40K | 2.30M | 3.72M | 5.11M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.64M | 4.83M | 5.03M | 4.58M | 4.63M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.64M | 4.83M | 5.03M | 4.58M | 4.63M |
| Operating Income | -4.64M | -4.83M | -5.03M | -4.58M | -4.63M |
| Income Before Tax | -4.50M | -4.72M | -4.71M | -2.29M | -705.10K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -4.50 | -4.72 | -4.71 | -2.29 | -0.71 |
| Earnings from Discontinued Operations | 6.41M | -2.31M | -3.61M | -12.13M | -13.61M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1.91M | -7.02M | -8.32M | -14.42M | -14.32M |
| EBIT | -4.64M | -4.83M | -5.03M | -4.58M | -4.63M |
| EBITDA | -1.81M | -2.05M | -2.22M | -1.76M | -1.80M |
| EPS Basic | -10.65 | -37.38 | -50.69 | -58.66 | -91.47 |
| Normalized Basic EPS | -0.71 | -1.56 | -3.01 | -2.15 | -0.25 |
| EPS Diluted | -10.65 | -37.38 | -50.69 | -58.66 | -91.47 |
| Normalized Diluted EPS | -0.71 | -1.56 | -3.01 | -2.15 | -0.25 |
| Average Basic Shares Outstanding | 111.81M | 69.77M | 27.88M | 2.25M | 1.28M |
| Average Diluted Shares Outstanding | 111.81M | 69.77M | 27.88M | 2.25M | 1.28M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |